Introduction
In the Netherlands 41,000 patients suffer a stroke annually. 1 Late epileptic seizures develop in 2.5-15% of stroke patients. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Recurrent late symptomatic epileptic seizures develop in 48-89% of stroke patients with a first late seizure. 2, 5, 12, 13 The occurrence of a late epileptic seizure or epilepsy in stroke patients may adversely affect their outcome. Bogousslavsky et al. 14 described a persistent worsening of neurological outcome following epileptic seizures in stroke patients. De Reuck et al. 15 described a lower Mini-Mental State Examination score and a higher modified Rankin score (mRS), implying worsening of neurological state in stroke patients with epilepsy compared to stroke patients without epilepsy. In patients with intracerebral haemorrhage, the occurrence of epileptic seizures is associated with an increase in midline shift and a worsening of neurological outcome. 16 In contrast with these results, Paolucci et al. 12 described no influence of epileptic seizures on rehabilitation outcome. The influence of epileptic seizures in stroke patients on mortality remains unclear. [17] [18] [19] [20] The pathophysiology of the development of early and late epileptic seizures is unclear. Several authors 21, 22 suggested a different pathophysiological process underlying both conditions. Late seizures are assumed to be the result of the complex process of epileptogenesis during which the seizure threshold is lowered through a complicated chain of neuronal changes, whereas early seizures may rather be the result of acute excitatory activity due to glutamate release. Therefore, in our trial we focused on the prevention of late seizures only.
In the ideal situation patients with a high risk of developing late epileptic seizures should be treated prophylactically with a drug that prevents epileptogenesis and has few side effects. Several antiepileptic drugs (AEDs) have been tested for their ability to prevent seizures associated with fever, alcohol, malaria, perinatal asphyxia, contrast media, tumors, craniotomy and traumatic brain Introduction: Epileptic seizures in stroke patients are a common complication and adversely affect neurological outcome. We tried to perform a trial aimed at preventing the development of late poststroke seizures using levetiracetam. Levetiracetam is assumed to have anti-epileptogenic properties and might be suitable to prevent late epileptic seizures in stroke patients. Methods: Stroke patients with a cortical syndrome and a modified Rankin score ! 3 or NIHSS ! 6 were treated with either levetiracetam 1500 mg daily divided in two doses or placebo during 12 weeks following stroke. Treatment was started within 7 days following stroke onset. Results: Only 16 patients were included in this trial. Problems during the execution of this prophylactic trial concerned the assessment of the occurrence of epileptic seizures, a very slow inclusion rate, the use of anticonvulsive co-medication, continuation of the trial medication after discharge, and the evaluation of possible side effects of the trial medication. Discussion: Due to too few participants, no conclusions could be drawn regarding the ability of levetiracetam to prevent poststroke seizures. The problems encountered during execution of this trial seem to be inherent to performing a trial aimed at preventing the development of epileptic seizures in stroke patients. Conclusions: A prophylactic trial in stroke patients aimed at preventing poststroke seizures and epilepsy seems not feasible.
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injury, but not in stroke patients. 23 So far, no controlled trial aimed at anti-epileptogenesis in stroke patients using an AED has been published. The need for such a trial was suggested by several authors. 12, 24 Recently, such a trial was also recommended in a Cochrane review. 25 In 2005 we started the ETLAS trial: 'Early Treatment with Levetiracetam After Stroke for the prevention of late seizures: a randomised placebo-controlled double-blind trial'. The aim of our trial was to investigate whether prophylactic treatment with an AED following stroke reduced the risk of late epileptic seizures or postponed the onset of late epileptic seizures or epilepsy.
For several reasons we were unable to complete this trial. In this paper we report the problems encountered by our group when performing this prophylactic trial. We wanted to report this negative result because in our opinion, the implementation problems of this trial are inherent to this area and seem unavoidable.
Methods

Design of the trial
The ETLAS trial was designed as a multicentre, randomised, placebo-controlled, double-blind clinical trial. Primary endpoint of the trial was a first late epileptic seizure, defined as an unprovoked epileptic seizure more than 1 week after stroke. 26 Secondary endpoints were 'time to event' (period between stroke and the occurrence of a late epileptic seizure), occurrence of early epileptic seizures within 7 days after stroke, seizure severity, neurological function, neurocognitive function, handicap score, quality of life, and the occurrence of side effects of the trial medication. Fig. 1 illustrates the trial design. The trial was approved by the local medical ethics committee and board of directors of each participating centre. All patients or their legal representatives gave their written informed consent. Adult patients were recruited from the neurological ward at the University Hospital Maastricht starting in August 2005. From August 2006 the trial also started in the second centre, a large peripheral hospital in the south of the Netherlands. Patients with either lobar intracerebral haemorrhage or ischemic stroke with a cortical syndrome and mRS ! 3 or National Institutes of Health stroke severity (NIHSS) score ! 6 were asked to participate. Exclusion-criteria were previous history of epilepsy or treatment with an AED, life expectation less than 1 month due to stroke or other life-threatening comorbidity, and participation in another intervention trial. Treatment with thrombolytic drugs was no exclusion criterion. Trial medication was started between 48 h till 7 days after stroke. Patients were randomised to treatment with levetiracetam (LEV) or placebo. Trial medication, provided by UCB Pharma, consisted of either placebo tablets or 250 mg LEV tablets. These tablets were used to make boxes which were filled at random (according to a computerised randomisation list) by a pharmacist, and given consecutive numbers from 1001, 1002, etc. On each inclusion the trial medication with the lowest number was provided by the hospital pharmacist. The allocation of the trial medication was therefore blind to the patient and the investigators. The trial medication was gradually increased. On the first day of inclusion the patient received twice daily 1 tablet, the second day twice daily 2 tablets and the third day twice daily 3 tablets. When tolerated, this dose was kept constant for 12 weeks, after which the trial medication was tapered off by one tablet each 3 days and eventually discontinued. Total treatment time was therefore 14 weeks and 3 days. The target dose of LEV was two times daily 750 mg, but we allowed for lowering of the dose to twice daily 500 mg or even twice daily 250 mg when side-effects or medical problems, such as reduced renal clearance rate, occurred.
We informed the staff, nurses at the neurology wards and the nursing home doctors at the referral nursing homes of first choice about our trial with an oral presentation and written information on trial details. Also, in each patient chart a coloured leaf was available with information on the trial and telephone numbers of the trial investigators. On discharge from the hospital, a letter, containing information about the trial, tapering schedule and contact information was provided along with the trial medication.
Follow-up and outcome scores
Follow-up visits took place at week 1, 6, 16 and 52 after inclusion, either at the outpatient clinic, in the nursing home, rehabilitation centre or at the patients' home. At week 26 and week 39, the patients or their caregivers were contacted by telephone to inquire about the occurrence of possible epileptic seizures. We recorded the degree of handicap using the mRS, a six item scale ranging from '0 = no symptoms at all' to '6 = dead', at inclusion, week 6, 16, and 52. The NIHSS, a 15-item impairment scale which total scores ranging from 0 to 42, with higher values reflecting a higher stroke severity, was recorded at inclusion and at week 52. The Barthel index (BI), which is a 10 item questionnaire about
independence in activities of daily living (ADL), with scores ranging from 0 to 20, in which '0' signifies total dependence and '20' total independence, was recorded at week 6, 16 and 52. The EuroQol, a generic quality of life measure, was recorded at the same follow-up moments as the BI. The side-effect in AED treatment questionnaire (SIDAED) was recorded at week 1 and week 6. This is a 46-item scale, which includes items in several categories such as general CNS, behaviour, depressive symptoms, and cognitive function (in Fig. 2 all categories are listed). Of each item the severity of the problem (mild, moderate, or severe) and the duration of the problem (several weeks, several months, longer than 6 months) was recorded. 27 Neurocognitive function was tested using the Computerised Visual Searching Task (CVST), an adaptation of Goldstein's Visual Searching Task, which is part of the FePsy computerised neuropsychological test method. 28 The CVST assessed mental speed. Patients had to compare a centred grid pattern with 10 surrounding patterns, one of which was identical to the target pattern. The test consisted of 20 trials and gave an indication of the speed of information processing and perceptual mental strategies.
Sample size estimation
Sample size calculation was based on the following assumptions: (1) patients with a cortical syndrome and mRS ! 3 have a risk of 13% of late seizures, 29 (2) treatment reduces this risk (13%)
to 5% (RRR = 62%). The primary factor type-1 (a) was chosen at the 5% level. Statistical power was chosen to be 1 À b = 80%. The power calculation based on percentage difference (change from 13% to 5% epilepsy) then yielded 200 patients per arm.
Discussion of the design
Trial population
The advantages of prophylactic medication in terms of prevention of epileptic seizures must be balanced against the disadvantages of treating all patients, which means taking medication daily and being exposed to the risk of side effects, especially for patients who would never had developed epileptic seizures. To improve the balance between efficacy of the drug and the occurrence of side effects, an effective drug with few sideeffects should be selected and only patients with a high risk of developing poststroke epilepsy should be treated.
Several factors have been associated with the occurrence of late epileptic seizures in stroke patients: age, stroke severity, stroke localisation or cortical syndrome, stroke type, and the occurrence of early seizures. 6, [11] [12] [13] [30] [31] [32] [33] [34] [35] [36] [37] Nonetheless, there is still debate about which factors have a significant contribution to the risk of developing poststroke epileptic seizures. In our centre Heuts-van Raak 29 performed a prospective study in poststroke patients. They reported a percentage of 13% late onset seizures in patients with an ischemic stroke, clinically a cortical syndrome and a mRS ! 3. The mRS is an outcome scale. It is more rational to use a stroke severity scale when selecting patients eligible for a trial. Therefore, we decided to use both the mRS and the NIHSS, a frequently used stroke severity scale, as inclusion criterion. A NIHSS ! 6 was chosen because, in our opinion this represented a stroke severity with mRS ! 3 best. 38 
Trial medication
LEV is assumed to have anti-epileptogenic properties. When we started this study, this effect had been tested in several animal models, e.g. amygdala kindled rats, 39 corneally kindled mice, 40 and spontaneous epileptic rats. 41, 42 After initiation of our trial in 2005, more reports have been published about the antiepileptogenic effects of LEV in animal models. [43] [44] [45] [46] Sugaya et al. 44 suggested that prophylactic use of LEV for several weeks after a cerebral insult, like cerebral infarction, could provide long-lasting protection in the prevention of the late onset of spontaneous epilepsy. Early treatment with LEV in stroke patients does not seem harmful with regard to the effect on ischemic brain tissue. 47 Tolerability of LEV in clinical practice is good. [48] [49] [50] [51] We choose a target LEV dose of two times daily 750 mg, which is a clinically accepted dose with acceptable tolerability and high enough to be effective.
Start of treatment
An early start of treatment seemed necessary to allow for the best possible anti-epileptogenic effects, when one considers epileptogenesis as a continuous process which starts immediately following stroke. Due to logistic reasons, such as the need to provide extensive patient information to guarantee compliance for the duration of 12 months, and to give patients and their relatives time to consider inclusion in the trial, initiation of treatment was not started within 48 h. To allow participation of patients who could not give informed consent, e.g. due to somnolence in severe stroke, we extended the inclusion period to 7 days after stroke.
Treatment duration and follow-up
The length of the intervention period (12 weeks) was based on calculations from the study by Heuts-van Raak. 29 Within the first year after stroke, the occurrence of late epileptic seizures was evenly distributed without peak periods. The treatment period should be long enough to prevent epileptogenesis. However, longer treatment periods increase the risk that treatment is anti-convulsive instead of anti-epileptogenic, as some patients would have had epileptic seizures if the AED would not have been given. The purpose of this trial was not to study the anti-convulsive effect of LEV, but to test the hypothesis of an anti-epileptogenic or prophylactic effect. The length of our follow-up period was based on data indicating that approximately two third of the late epileptic seizures occur within 1 year after stroke.
11,13
Estimated inclusion rate
Before starting this trial we tried to estimate the number of patients eligible for inclusion in this trial. In this period yearly about 340 patients were admitted to our hospital with a stroke, of which 62% had an ischemic stroke with a cortical syndrome, and 7% had a lobar intracerebral haemorrhage (resulting in 235 available patients per year). Because in this prophylactic trial only first-ever ischemic stroke patients with a predefined severity were suitable for inclusion, we estimated another 80 patients would not have the required severity of neurological deficit for inclusion or other medical problems preventing inclusion (resulting in 155 available patients per year). Furthermore, we estimated that two third would give informed consent. Hence, we would be able to include 100 patients a year. So, in our centre 2 years would be sufficient to include 200 patients. By inviting a second hospital to include similar numbers of patients, we supposed the necessary 400 patients could be included in 2 years, leading to a trial duration of 3 years, which seemed feasible.
Results
In the period from August 2005 until December 2006 we included 16 patients from the department of Neurology at the University Hospital Maastricht. No patients were included in the second centre. Therefore, we decided to end the trial prematurely.
In this period about 500 patients were admitted to our hospital with a stroke. Most patients, however, were not eligible for inclusion. Table 1 gives an overview of the reasons to exclude patients. It illustrates the most crucial problem that we encountered in our trial. The 'label' of stroke combines a heterogeneous group of patients with a stroke and many complicating factors. Due to these factors, in addition to exclusion based on stroke type and stroke severity, many patients were ineligible for this prophylactic trial.
Only 31 of the 500 patients were eligible for our trial. Of these, 15 refused, and 16 gave informed consent. Of the 16 included patients, nine patients were randomised to LEV, seven to placebo.
Reasons for the high refusal rate were fear of side-effects, disapproval of the experimental character of the trial, which meant a 50% chance of treatment with placebo ('taking pills for nothing') or relatives thinking that the trial would give too large a burden to the already ill patient. Patients were at a vulnerable phase in their lives, they just suffered a major life event. They did not want to be bothered with scientific investigations. Table 2 shows results of the mRS, NIHSS, BI, and VAS score of the EuroQol per group and overall.
Primary endpoint
In four patients (4, 9, 12, 16) possible epileptic seizures were reported. One episode was reported the day after the event; the other episodes were only reported at the next follow-up visit.
In two patients a diagnosis of late epileptic seizures was considered by the treating physician: in patient 9, who was randomised to placebo and in patient 16, who was randomised to LEV. After revision of the chart of patient 9 by one of our experienced neurologists (MdK), the diagnosis poststroke epilepsy was confirmed. This patient received carbamazepine (CBZ) to treat his poststroke seizures and because seizures recurred, LEV was added.
Patient 16 had absence-like episodes and collapses. She was treated with CBZ because her treating physician considered these episodes to be poststroke epilepsy. After several weeks of CBZ treatment, she had a pacemaker implanted because of a sick sinus syndrome. The collapses then disappeared. After revision of her medical chart the diagnosis of poststroke epilepsy was considered very unlikely by our experienced neurologist (MdK).
In patients 4 and 12, both randomised to LEV, the episodes were diagnosed as vasovagal collapse and both a vasovagal collapse and a recurrent stroke, respectively. Admission for minor stroke and progression of neurological deficit several days after admission, or occurrence of symptoms several days before presentation in our hospital preventing inclusion within 7 days following stroke 5 Decreased renal function 3 Severe co-morbidity with a short life-expectancy 2 No informed consent possible (due to, e.g. aphasia or mental retardation, and no family members available to give consent) <1 Missed due to admission to other ward <1 History of other brain disease (e.g. pituitary tumor) <1
Co-medication with anticonvulsive effects
Five patients were treated with co-medication which may have influenced the occurrence of epileptic seizures. During follow-up, two patients (9, 16) received AEDs because they were diagnosed as having poststroke seizures (correctly in patient 9, undeserved in patient 16). Two patients (3, 11) received AEDs to treat neuropathic pain due to a thalamic syndrome. Patient 3 was treated with carbamazepine and patient 11 with pregabalin. Two patients (5, 9) used benzodiazepines as sleep medication. Without this comedication, we would possibly have recorded more epileptic seizures during follow-up.
Side effects
To evaluate the impact of side-effects during the treatment with LEV, the SIDAED questionnaire was recorded. At the first follow-up after inclusion, which is one week after start of the trial medication, 12 patients completed the SIDAED list. Data from four patients are missing: patient 13 died 6 days after inclusion, patient 12 had severe aphasia preventing adequate answers to the questions, patient 7 had behavioural problems (agitation and anxiety) and could not cooperate, and in patient 16 the list was forgotten at this follow-up point. At 6 weeks follow-up 4 patients did not fill out the questionnaire: three died (4, 13, 14) , and patient 12 still had severe aphasia. Therefore, the questionnaire was not recorded in 30% of the patients at both weeks 1 and 6. Patient 11 stopped taking the trial medication one week after initiation of the trial and therefore her side-effect list at week 6 can neither be used as a follow-up parameter in the LEV group, nor in the placebo group because she stopped taking her trial medication. Fig. 2 shows the percentage of problems per category, which were reported at week 1 and week 6. The number of problems at week 1 is higher in the LEV group than in the placebo group. However, some of these problems were reported to exist several months or longer than 6 months. Therefore, these problems cannot be caused by either stroke or side-effects of the trial medication but must reflect longer existing premorbid problems.
At week 6 no clear differences in complaints existed between the LEV and placebo group. Because data were not available for all patients at both follow-up points, comparison of the overall results at week 1 and 6 is not possible.
Adjustment of trial medication dose or discontinuation of trial medication
Patients 3, 15 and 16 received a lower dose of the trial medication due to renal dysfunction.
In patient 3 the trial medication was discontinued by his treating nursing home doctor without further consultation with the trial team and without tapering off the trial medication when the patient was transferred to a nursing home 48 days after inclusion in our trial. After unblinding the trial medication proved to be placebo.
In patient 9 the family requested lowering of the dose because of fear of side-effects (dizziness, cognitive complaints). He appeared to be treated with placebo.
The family of patient number 11 demanded discontinuation of the trial medication one week after start of the trial medication, because of the occurrence of visual hallucinations. As hallucinations have been reported as a side effect of LEV we tapered off the trial medication and discontinued it 20 days after start of the trial. She had been treated with LEV.
Lost to follow-up or died during follow-up
Three patients died during follow-up (4, 13, 14) , two of them received placebo, one received LEV. Patient 4 died in a nursing home. The coroner concluded this was caused by a second intracranial haemorrhage (autopsy was not performed). Patient 13 died 5 days after start of trial medication due to massive lung embolism (confirmed on autopsy). Patient 14 died at home. Paramedics concluded that a cardiac arrest was the cause of death (no autopsy).
In patient 16 follow-up at 1 year after inclusion was by telephone with a nurse. No visit was allowed due to a bad neurological state.
Discussion
The need for clinical studies to investigate the benefits of prophylactic treatment to prevent poststroke epilepsy is clear. 25 However, inherent to such a trial is a plethora of difficulties that has also been discussed by Herman. 52 In this paper we discuss the problems we met and which resulted in a premature ending of our trial. Only 16 patients (nine treated with LEV, seven with placebo) were included in the trial. One patient in the placebo group developed poststroke epilepsy. The number of included patients is far too low to determine the possible anti-epileptogenic effect of LEV in stroke patients. This paper intends to disclose the problems encountered in order to prevent future prophylactic trial failures.
The problems and complicating factors can be summarised as follows:
1. As shown in the results section selecting sufficient patients eligible for inclusion was difficult. Calculations based on our stroke registry did not give an adequate estimate of the number of patients suitable for inclusion. The majority of the patients either met exclusion criteria or had such co-morbidity that inclusion is impossible for practical reasons. With the present in-and exclusion criteria, each centre will only have a limited number of eligible patients. This means that a large multicentre and probably multinational trial is required to include sufficient patients in an anti-epileptogenesis trial. 2. The assessment of seizure like episodes in stroke patients was difficult. The occurrence of epileptic seizures may be missed by the patient itself, health personnel and family members. 53 In this trial, most episodes that possibly reflect an epileptic seizure were not mentioned to the examiner immediately. Generally, they were mentioned at the next follow-up visit, either spontaneously or on request, which caused a recall-bias. Some episodes may never have been mentioned. Seizures in stoke patients, in particular complex partial seizures may be difficult to recognize. 54 The differential diagnostic considerations included stroke recurrence, vasovagal collapse, limb shaking TIA, hypoglycaemia or other metabolic disturbances, cardiac arrhythmias with syncope, and hyperventilation. 55, 56 Therefore, measurement of the primary endpoint, the occurrence of late epileptic seizures, was difficult. 3. Furthermore, the use of benzodiazepines and AEDs as comedication caused a problem in this trial because these drugs have potential anticonvulsive effects. Without this co-medication, we would possibly have recorded more epileptic seizures during follow-up. These drugs were mostly prescribed by other treating physicians (general physician, rehabilitation doctor, nursing home doctor). This is part of good clinical practice, and could not be avoided. 4. A further difficulty in our trial was the evaluation of side-effects occurring during the administration of the trial medication. A reliable assessment of side-effects was considered important in order to balance the beneficial effects of preventing poststroke seizures, on the one hand, and the risk and severity of sideeffects when using prophylactic medication, on the other hand.
In this trial, symptoms which occurred during treatment with the trial medication may be related to the stroke, to comedication which is started at the onset of stroke, to comedication used prior to the stroke or to the trial medication. Furthermore, aphasia or inability to cooperate otherwise may limit the report of side effects of the trial medication.
At the first evaluation point at week 1, patients in the LEV group reported more possible side-effects than patients in the placebo group. However, part of these complaints were found to exist already before the trial medication was started and even before the stroke, and therefore could not be ascribed to treatment with the trial medication. At week 6 there were no differences in number of possible side effects. This could point to a disappearance of side-effects of the trial medication or comedication due to habituation, but also to a neurological recovery from stroke. A third explanation is that complaints which existed before the stroke may disappear to the background due to new complaints as a consequence of stroke and new medication. Evaluation of side-effects in patients with a recent stroke is also difficult because many complaints caused by a stroke are the same as complaints caused by side-effects of AEDs. 5. Continuation of trial medication after discharge from the neurological ward is an additional problem. Most stroke patients were admitted to the neurological ward for a limited period of time. After several days or, in some patients, weeks, patients were transferred to a nursing home or rehabilitation centre. Informing other health care workers (nurses, doctors) is crucial but also very difficult. Despite our measures to inform other health care personnel, as described in the methods section, continuation of trial medication after discharge appeared to be difficult. Also continuation of the trial medication when a patient was readmitted to our hospital for a non-neurological reason on another ward was difficult. 6. The influence of thrombolytic drugs has to be considered. Hafeez et al. 57 reported on a partial status epilepticus following administration of a thrombolytic drug. Rodan et al. 58 reported three patients with epileptic seizures following thrombolysis each with very good neurological recovery. A recent report suggests that thrombolysis may partly prevent the occurrence of late-onset seizures, probably by a better reperfusion of the ischemic brain regions. 59 We believe that stroke patients treated with a thrombolytic drug should not be excluded in a trial aimed at preventing poststroke seizures.
Conclusions
The problems arising in a prophylactic trial aimed at preventing poststroke seizures concern difficulties in assessing the primary endpoint, which is the occurrence of a first late epileptic seizure, a very slow inclusion rate due to few eligible patients, the use of comedication with anticonvulsive properties, difficulties to maintain patients on their treatment regimen during the trial, and difficulties in evaluating possible side effects of the trial medication.
In our opinion a prophylactic trial assessing the anti-epileptogenic efficacy of a short AED treatment period to prevent poststroke epilepsy is not feasible.
